BURLINGTON, Mass., Feb. 14, 2014 /PRNewswire/ -- inVentiv Health, offering best-in-class clinical, commercial and consulting services, today announced that Mytrus, Inc., a pioneer in electronic patient enrollment, has been recognized with a Best Practices Award from Clinical Informatics News for a project conducted for Pfizer, Inc.

Last spring, inVentiv Health took an equity position in Mytrus, Inc., as part of inVentiv's strategic focus on increasing clinical trial efficiency. inVentiv has developed one of the industry's broadest suite of technologies and services designed to speed patient and investigator recruitment, improve site feasibility and transform patient enrollment.

The award was presented to Mytrus during the 2014 Summit for Clinical Ops Executives (SCOPE) held last week in Miami. Established last year, the Best Practices Award from Clinical Informatics News recognizes clinical organizations for outstanding strategic innovation - partnerships, deployments, or collaborations that manifestly improve the clinical trial process. Nominees were judged by a panel that included two editors and five industry experts.

In the category of "Patient Data Management," Mytrus and Pfizer received a joint award for a complete direct-to-patient clinical trial system, code-named "Apollo." The technology used allowed patients in a trial to participate from home in everything from recruitment and informed consent to regular reporting of clinical data. The system also enabled the delivery of study data direct to participants upon the trial's conclusion.

"inVentiv is fully aligned with our clients' desire for faster drug development," said Paul Meister, CEO of inVentiv Health. "We invested in Mytrus because of its pioneering use of technology in electronic patient enrollment and this award further validates the use of such technology as an industry best practice. We congratulate Mytrus and Pfizer for this well-deserved honor."

Award finalists and winners were selected for their innovative use of clinical technologies including informatics, information technology, and knowledge management on a project or organizational level to achieve significantly improved results in clinical operations, clinical trial planning, or patient service. Other winners included Clinical Ink and Forte Research Systems.

Judges rated entries on innovation, importance, return on investment and likely industry impact, looking for examples that spotlighted the practical and positive deployment of novel technologies. Competitors included pharmaceutical companies, medical centers and clinical tools providers from around the world.

"We are honored to have worked closely with Pfizer in this important clinical trial which we believe will pave the way for many other new innovations in clinical research methods," said Anthony Costello, CEO of Mytrus. "We are convinced that simplifying clinical trials for patients is a key to dramatically changing the time and cost of bringing new drugs to market."

This is the second prestigious award in six months for Mytrus, which last August received Frost & Sullivan's North American Product Leadership Award in Clinical Trials for their pioneering electronic informed consent application, enroll™. Frost & Sullivan, a respected global research organization that tracks more than 250,000 companies, compared Mytrus to other market competitors in a rigorous review that touched on several elements of product design, adoption, ease of use and market potential. Frost & Sullivan credited Mytrus with having developed a disruptive innovation that made the cumbersome, but critical process of informed consent simple and efficient for patients – while offering trial sponsors and regulators new opportunities to collect and track important informed consent data analytics.

About MytrusFounded in 2009, Mytrus is a California-based clinical technology and services company built on the idea that modern technologies can enable people to safely and effectively participate in clinical trials without requiring them to live near a study center. The company's proprietary methods can dramatically improve patient recruitment timelines, increase patient retention and reduce overall study costs for sponsors. Learn more about Mytrus at http://www.mytrus.com or find the company on Facebook and Twitter @mytrus.

About inVentiv HealthinVentiv is a leading global provider of best-in-class clinical, commercial and consulting services to the life science sector. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise allow us to serve as a strategic partner for companies facing a complex operating, regulatory and reimbursement environment. inVentiv clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients. For more information, visit http://www.inVentivHealth.com.